Related Experiment Video
Updated: Jun 1, 2025

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
Published on: December 9, 2010
Pediatric Formulation Optimization Using a Rational Design: Exploring Amorphous Solid Dispersion Technology with
Izabelle Amorim Ferreira Boza1, Stéfani Laise da Silva1, Nicolly Bittencourt Guedes2
1Department of Chemistry, Center for Physical and Mathematical Sciences, Federal University of Santa Catarina, Florianópolis, SC, 88040-900, Brazil.
Insights
Developing pediatric antifungal formulations for terbinafine hydrochloride (TER) is challenging due to its low solubility. Researchers identified Soluplus® as a promising carrier for amorphous solid dispersions, enhancing TER solubility and bioavailability in children.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery
- Pediatric Formulations
Background:
- Pediatric formulations face unique challenges, especially for drugs like terbinafine hydrochloride (TER), an antifungal with low aqueous solubility.
- Tinea capitis, a common pediatric fungal infection, requires effective oral treatments, but TER's poor solubility hinders oral bioavailability.
Purpose of the Study:
- To rationally select suitable, pediatric-approved carriers for enhancing TER's apparent solubility.
- To develop amorphous solid dispersions (ASDs) of TER using spray drying for improved oral bioavailability in pediatric patients.
Main Methods:
- Evaluated solubility parameters, equilibrium solubility, and pediatric dose numbers for carrier selection.
- Utilized Plasdone S-360 ULTRA®, HPMCAS L, and Soluplus® as potential carriers.
- Characterized drug-carrier interactions and solid-state properties using various techniques.
- Prepared ASDs of TER using spray drying with the selected carrier.
Main Results:
- Solubility of TER was pH-dependent, with highest solubility observed in pH 6.5 buffer with 10% Soluplus®.
- Soluplus® yielded the lowest pediatric dose number (0.23) for children over 6 years old.
- Spray-dried ASDs significantly enhanced TER's apparent solubility and maintained prolonged supersaturation.
- No phase transitions or significant drug-carrier interactions were observed.
Conclusions:
- Soluplus® is a suitable carrier for developing TER amorphous solid dispersions for pediatric oral formulations.
- Spray-dried ASDs of TER with Soluplus® offer a promising strategy to improve oral bioavailability and efficacy in children.
- This approach addresses the challenges of developing effective oral antifungal treatments for pediatric patients.
Abstract:
Developing orally administered pediatric formulations presents significant challenges due to the unique characteristics of pediatric patients. Terbinafine hydrochloride (TER), a powerful antifungal agent, is effective against various fungal infections, including Tinea capitis, which is common in children. However, its low aqueous solubility necessitates innovative pharmaceutical strategies to enhance its effectiveness. This study describes a rational approach to selecting suitable carriers, approved for use in children, to increase the apparent solubility of TER and to guide the development of amorphous solid dispersions containing this drug. Assessments of solubility parameters, equilibrium solubility measurements, and calculations of pediatric dose numbers guided formulation development using theoretical and experimental methodologies. Carriers like Plasdone S-360 ULTRA®, HPMCAS L, and Soluplus® demonstrated favorable solubility parameter values with TER, indicating potential for drug solubilization. The solubility of TER was strongly dependent on pH. In buffer pH 6.5 containing 10% (w/v) of Soluplus®, TER presented the highest solubility value. The solid-state characterization techniques employed to assess the precipitate formed after equilibrium solubility studies during preformulation demonstrated that there were no phase transitions and no significant interactions between the drug and the evaluated carriers. Furthermore, the results demonstrate that Soluplus® achieved the lowest dose number (0.23) for pediatric patients over 6 years old. So, it was selected for preparing the amorphous solid dispersion via spray drying, which significantly enhanced the apparent solubility of TER while maintaining prolonged supersaturation, offering a promising alternative for developing solid formulations of this drug, particularly for pediatric patients, as it aims to improve oral bioavailability.
Related Concept Videos
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Biopharmaceutics and Pharmacokinetics: Overview
Factors Influencing Drug Absorption: Drug Dissolution
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

